미국 · 보도자료 · Candel Therapeutics · 2026-09-30 12:30
전립선암 치료제 임상서 지속적인 면역 활성화 효과 확인
NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced novel immunological biomarker data from the ongoing phase 2 PrTK05 trial ( NCT07332000 ) in patients with intermediate-ri
Candel Therapeutics 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
